Core Insights - The company reported a significant increase in product revenue and total revenue for the fiscal year 2025, with product revenue reaching 37.77 billion yuan, a year-on-year increase of 39.9%, and total revenue at 38.205 billion yuan, up 40.4% [1] - The net profit attributable to the parent company was 1.422 billion yuan, while total assets increased by 34.1% to 57.423 billion yuan, and equity attributable to the parent company rose by 26.6% to 30.601 billion yuan [1] Product Performance - The global sales of Baiyueze® reached 28.067 billion yuan, marking a 48.8% year-on-year growth, solidifying its position as a global leader in the BTK inhibitor market [2] - Sales in the U.S. amounted to 20.206 billion yuan, a 45.5% increase, while European sales were 4.265 billion yuan, up 66.4%, and sales in China totaled 2.472 billion yuan, increasing by 33.1% [2] - Bai Ze An® achieved global sales of 5.297 billion yuan, reflecting an 18.6% year-on-year growth, and sales from Amgen's licensed products reached 3.471 billion yuan, up 33.6% [2] Clinical Development and Regulatory Approvals - Baiyueze® is the most widely approved BTK inhibitor globally, with over 45 clinical trials conducted across more than 30 countries, enrolling over 7,900 patients [3] - The drug has received regulatory approvals in over 75 markets and demonstrated significant benefits in progression-free survival (PFS) in clinical trials, reinforcing its status as a preferred BTK inhibitor [3] - Bai Ze An® has shown potential across various tumor types, with clinical trials involving over 15,800 participants in more than 33 countries, and has been approved in over 50 markets [4] - The company plans to submit new indications for Bai Ze An® in the U.S. and China in the first half of 2026, with expectations for regulatory decisions in Japan by the second half of 2026 [4]

Core Insights - The company reported a total revenue of 38.205 billion yuan for the fiscal year 2025, representing a year-on-year growth of 40.40% [1] - The net profit attributable to shareholders was 1.422 billion yuan, a significant recovery from a net loss of 4.978 billion yuan in the same period last year [1] - The basic earnings per share stood at 1 yuan [1] Revenue Breakdown - Product revenue reached 37.770 billion yuan, up from 26.994 billion yuan in the previous year [1] - The growth in product revenue was primarily driven by sales of Baiyueze® (Zebutinib), licensed products from Amgen, and Baizean® (Tislelizumab) [1]

A 股代码：688235 A 股简称：百济神州 公告编号：2026-002 港股代码：06160 港股简称：百济神州 美股代码：ONC 百济神州有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 特别提示： 本公告所载的百济神州有限公司（以下简称"百济神州"或"公司"）2025 年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以公司披露 的经审计后的 2025 年年度报告为准，提请投资者注意投资风险。 本公告财务数据按中国企业会计准则编制并呈列。 本公司已于 2026 年 2 月 26 日同步发布了根据美国公认会计原则及美国证券 交易委员会适用规则编制的截至 2025 年 12 月 31 日止年度经审计财务业绩，提请投 资者注意与本公告区别。 1 一、2025 年度主要财务数据和指标 单位：人民币千元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | --- | --- | --- | --- | | 营业总收入 | 38,204,601 | 27,213, ...

格隆汇2月26日丨百济神州(688235.SH)公布，预计2026年营业收入将介于人民币436亿元至450亿元之 间，毛利率约为80%区间的高位，营业收入扣除经调整的经营成本费用将介于人民币98亿元至105亿元 之间。 ...

Financial Performance - In Q4 2025, the company reported total global revenue of $1.5 billion, a year-on-year increase of 33% [1] - For the full year 2025, total global revenue reached $5.3 billion, reflecting a 40% year-on-year growth [1] - Adjusted net profit for Q4 2025 was approximately $225 million, a significant increase of 1,297% year-on-year [1] - The full year adjusted net profit for 2025 was about $918 million, marking a return to profitability [1] - Free cash flow for Q4 2025 was $380 million, an increase of $397 million compared to the same period last year [1] - For the full year 2025, free cash flow totaled $942 million, an increase of $1.6 billion year-on-year [1] - The revenue guidance for the full year 2026 is projected to be between $6.2 billion and $6.4 billion [1] Product Performance - The global sales of Baiyueze (Zebutinib) in Q4 2025 reached $1.1 billion, a 38% year-on-year increase [1] - The annual global sales of Baiyueze for 2025 were $3.9 billion, representing a 49% growth compared to the previous year [1] - Global sales of Baizean (Trelatuzumab) in Q4 2025 were $18.2 million, an 18% increase year-on-year [1] - The total annual sales of Baizean for 2025 were $73.7 million, reflecting a 19% year-on-year growth [1] Strategic Insights - The strong financial performance in Q4 2025 and for the full year underscores the company's evolution as a leader in the global oncology treatment sector [2] - The company has established a durable competitive advantage in clinical development and production, supported by a differentiated R&D pipeline [2] - Baiyueze has solidified its position as a global leader in the BTK inhibitor space, with extensive regulatory approvals and strong clinical recognition [2] - The company is expanding the indications and reimbursement coverage for Baizean in major global markets [2] - With several cornerstone hematologic oncology products nearing commercialization and promising data from solid tumor pipelines, the company aims for sustainable global growth [2]

每经AI快讯，2月26日，百济神州发布公告称，2025年第四季度，全球总收入达15亿美元，同比增长 33%；全年全球总收入达53亿美元，同比增长40%。第四季度和全年，GAAP稀释每股美国存托股 （ADS）收益分别为0.58美元和2.53美元；非审计公认会计准则下摊薄后每股美国存托股收益分别为 1.95美元和8.09美元。2026年全年总收入指引为62亿美元至64亿美元之间。 ...

Core Insights - The company reported strong financial performance for Q4 2025 and the full year, indicating a significant growth trajectory in the oncology treatment sector [1][2] - The adjusted net profit for Q4 2025 reached approximately $225 million, a year-on-year increase of 1,297%, while the full-year adjusted net profit was about $918 million, marking a return to profitability [1] - The company projects total revenue for 2026 to be between $6.2 billion and $6.4 billion, reflecting continued growth expectations [1] Financial Performance - Global total revenue for Q4 2025 was $1.5 billion, a 33% increase year-on-year; the full-year global total revenue reached $5.3 billion, up 40% [1] - Free cash flow for Q4 2025 was $380 million, an increase of $397 million compared to the same period last year; the full-year free cash flow was $942 million, up $1.6 billion year-on-year [1] Product Performance - The global sales of Baiyueze® (Zebutinib) in Q4 2025 amounted to $1.1 billion, a 38% year-on-year increase; the annual global sales reached $3.9 billion, up 49% [1] - Global sales of Baizean® (Trelatuzumab) for Q4 2025 were $18.2 million, an 18% increase year-on-year; the full-year global sales were $73.7 million, a 19% increase [1] Strategic Positioning - The company emphasizes its strong position as a leader in the global oncology treatment field, supported by a robust and differentiated R&D pipeline [2] - Baiyueze® has established a leading position in the BTK inhibitor market, backed by extensive regulatory approvals and strong clinical efficacy data in chronic lymphocytic leukemia (CLL) [2] - The company is expanding the indications and reimbursement coverage for Baizean® in major global markets, with several late-stage hematologic oncology products nearing commercialization [2]

2025年第四季度和全年，GAAP净利润为6,700万美元和2.87亿美元，与上年同期净亏损相比分别增加 2.18亿美元和9.32亿美元，主要得益于收入增长及经营杠杆改善。2025年全年GAAP净利润包括7,600万 美元的股权投资减值费用、2,500万美元的非经常性税务项目费用，以及在特定司法管辖区因时间性因 素产生的2,000万美元税务费用，这些费用主要发生在第四季度。 格隆汇2月26日丨百济神州(06160.HK)公布截至2025年12月31日止三个月未经审核业绩及截至2025年12 月31日止全年经审核业绩。产品收入：2025年第四季度产品收入为15亿美元，同比增长32%，全年产品 收入为53亿美元，同比增长40%。产品收入占公司总收入99%。 ...

百济神州(06160.HK)公告，2025年第四季度，全球总收入达15亿美元，同比增长33%；全年全球总收入 达53亿美元，同比增长40%。百悦泽第四季度全球销售额达11亿美元，同比增长38%；全球年销售额达 39亿美元，同比增长49%。第四季度和全年，GAAP稀释每股美国存托股份(ADS)收益分别为0.58美元和 2.53美元；非GAAP稀释每股ADS收益分别为1.95美元和8.09美元。2026年全年总收入指引为62亿美元至 64亿美元之间。 来源：滚动播报 ...

Core Viewpoint - BeiGene (6160.HK) reported a significant increase in global revenue for Q4 2025 and the entire year, indicating strong growth in its financial performance [1] Financial Performance - Global total revenue reached $1.5 billion in Q4 2025, representing a 33% year-over-year increase [1] - Total global revenue for the year amounted to $5.3 billion, reflecting a 40% year-over-year growth [1] - Q4 global sales for the product Baiyueze reached $1.1 billion, up 38% year-over-year [1] - Annual global sales for Baiyueze were $3.9 billion, showing a 49% year-over-year increase [1] Earnings Per Share - GAAP diluted earnings per American Depositary Share (ADS) were $0.58 for Q4 and $2.53 for the full year [1] - Non-GAAP diluted earnings per ADS were $1.95 for Q4 and $8.09 for the full year [1] Future Guidance - The company provided revenue guidance for 2026, projecting total revenue between $6.2 billion and $6.4 billion [1]